Double-crossed: Why crossover in clinical trials may be distorting medical science

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 11, Issue 5, 2013, Pages 625-627

  Prasad, Vinay ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DULOXETINE; INIPARIB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; OLAPARIB; TORCETRAPIB; VANDETANIB;

CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; COMPETITIVE INHIBITION; CONTROL GROUP; CROSSOVER PROCEDURE; DISEASE COURSE; ENZYME INHIBITION; HEART FAILURE; HUMAN; MEDICINE; MORTALITY; NEUROPATHY; NOTE; OVARY CANCER; OVERALL SURVIVAL; PNEUMONIA; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY FAILURE; SEPSIS; SURVIVAL; THYROID CANCER; TRIPLE NEGATIVE BREAST CANCER;

EID: 84877999327     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2013.0077     Document Type: Note

References (7)

1. Fojo T, Amiri-Kordestani L, Bates SE. Potential pitfalls of crossover and thoughts on iniparib in triple-negative breast cancer. J Natl Cancer Inst 2011;103:1738-1740.
2. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012;366:1382-1392.
3. AstraZeneca. Updates on olaparib and TC-5214 development programmes. Available at: http://www.astrazeneca.com/Media/Press-releases/Article/20111220- az-updates-olaparib-TC5214-development. Accessed November 3, 2011.
4. Moore TJ, Furberg CD. The safety risks of innovation: the FDA's expedited drug development pathway. JAMA 2012;308:869-870.
5. Justice R, for the FDA. Summary review for regulatory action: NDA 022405, Vandetanib. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/nda/ 2011/022405Orig1s000SumR.pdf Accessed April 22, 2013.
6. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109-2122.
7. Lavoie Smith EM, Pang H, Cirrincione C, et al. CALGB 170601: a phase III double blind trial of duloxetine to treat painful chemotherapy-induced peripheral neuropathy (CIPN) [abstract]. J Clin Oncol 2012;30(Suppl 15):Abstract CRA9013.